

Nicolas Meyer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9345460/publications.pdf>

Version: 2024-02-01

42
papers

5,138
citations

361045

20
h-index

253896

43
g-index

46
all docs

46
docs citations

46
times ranked

8394
citing authors

#	ARTICLE	IF	CITATIONS
1	Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma. <i>New England Journal of Medicine</i> , 2015, 372, 2006-2017.	13.9	2,489
2	Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1558-1568.	5.1	827
3	TNF± blockade overcomes resistance to anti-PD-1 in experimental melanoma. <i>Nature Communications</i> , 2017, 8, 2256.	5.8	284
4	Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial. <i>European Journal of Cancer</i> , 2017, 86, 334-348.	1.3	212
5	Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. <i>Lancet Oncology</i> , The, 2015, 16, 729-736.	5.1	198
6	The TNF Paradox in Cancer Progression and Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 1818.	2.2	198
7	Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: A systematic review and meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 992-1002.	0.6	162
8	Psoriasis: an epidemiological evaluation of disease burden in 590 patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 1075-1082.	1.3	87
9	Geoeidemiologic considerations of auto-immune pemphigus. <i>Autoimmunity Reviews</i> , 2010, 9, A379-A382.	2.5	82
10	Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial. <i>Clinical Cancer Research</i> , 2021, 27, 1037-1047.	3.2	55
11	Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma. <i>Journal of Oncology</i> , 2018, 2018, 1-9.	0.6	53
12	Pruritus in Cutaneous T-cell Lymphomas: Frequent, Often Severe and Difficult to Treat. <i>Acta Dermato-Venereologica</i> , 2010, 90, 12-17.	0.6	51
13	Follow-Up of Patients With Complete Remission of Locally Advanced Basal Cell Carcinoma After Vismodegib Discontinuation: A Multicenter French Study of 116 Patients. <i>Journal of Clinical Oncology</i> , 2019, 37, 3275-3282.	0.8	41
14	High-frequency ultrasonography but not 930nm optical coherence tomography reliably evaluates melanoma thickness <i>in vivo</i> : a prospective validation study. <i>British Journal of Dermatology</i> , 2014, 171, 799-805.	1.4	39
15	RhoB Promotes Cancer Initiation by Protecting Keratinocytes from UVB-Induced Apoptosis but Limits Tumor Aggressiveness. <i>Journal of Investigative Dermatology</i> , 2014, 134, 203-212.	0.3	28
16	Awareness, knowledge and attitudes towards sun protection among skin cancer-treated patients in France. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2007, 21, 070209222700006-???	1.3	27
17	Topical methyl aminolevulinate photodynamic therapy for management of basal cell carcinomas in patients with basal cell nevus syndrome improves patient's satisfaction and reduces the need for surgical procedures. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 861-864.	1.3	25
18	Efficacy of anti-programmed cell death-1 immunotherapy for skin carcinomas and melanoma metastases in a patient with xeroderma pigmentosum. <i>British Journal of Dermatology</i> , 2018, 178, 1199-1203.	1.4	25

#	ARTICLE	IF	CITATIONS
19	Vemurafenib significantly decreases glomerular filtration rate. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 978-979.	1.3	24
20	Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy. <i>British Journal of Cancer</i> , 2018, 119, 193-199.	2.9	21
21	Anti-TNF, a magic bullet in cancer immunotherapy?. , 2019, 7, 303.		21
22	Complete response of a metastatic porocarcinoma treated with paclitaxel, cetuximab and radiotherapy. <i>European Journal of Cancer</i> , 2018, 90, 142-145.	1.3	19
23	Cutaneous T Cell Lymphoma Complicating Severe Atopic Dermatitis. <i>Dermatology</i> , 2009, 218, 168-171.	0.9	16
24	Tumour lysis syndrome: an unexpected adverse event associated with ipilimumab. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e73-e74.	1.3	15
25	Sentinel lymph node biopsy for melanoma is becoming a consensus: a national survey of French centres involved in melanoma care in 2008. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 1230-1235.	1.3	14
26	Factors associated with sun protection compliance: results from a nationwide cross-sectional evaluation of 2215 patients from a dermatological consultation. <i>British Journal of Dermatology</i> , 2014, 170, 1327-1335.	1.4	14
27	Enzalutamide induced acute generalized exanthematous pustulosis. <i>Journal of Dermatological Case Reports</i> , 2016, 10, 35-38.	1.1	14
28	BRAF V600 inhibitor discontinuation after complete response in advanced melanoma: a retrospective analysis of 16 patients. <i>British Journal of Dermatology</i> , 2017, 177, e94-e95.	1.4	11
29	Incidence of Auto-Immune Pemphigus in the Midi-Pyrénées Region in 2002-2006. <i>Dermatology</i> , 2010, 220, 97-102.	0.9	10
30	Benefit of the nivolumab and ipilimumab combination in pretreated advanced melanoma. <i>European Journal of Cancer</i> , 2018, 93, 147-149.	1.3	10
31	Advanced Cutaneous Squamous Cell Carcinoma Is Associated with Suboptimal Initial Management in a Cohort of 109 Patients. <i>Dermatology</i> , 2019, 235, 516-521.	0.9	7
32	A Multicenter Phase II Study of Pazopanib in Patients with Unresectable Dermatofibrosarcoma Protuberans. <i>Journal of Investigative Dermatology</i> , 2021, 141, 761-769.e2.	0.3	7
33	Efficacy of sonic hedgehog inhibitors rechallenge, after initial complete response in recurrent advanced basal cell carcinoma: a retrospective study from the CARADERM database. <i>ESMO Open</i> , 2021, 6, 100284.	2.0	7
34	Understanding the Lived Experiences of Patients With Melanoma: Real-World Evidence Generated Through a European Social Media Listening Analysis. <i>JMIR Cancer</i> , 2022, 8, e35930.	0.9	7
35	Physicians involved in the care of patients with high risk of skin cancer should be trained regarding sun protection measures: evidence from a cross sectional study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 19-23.	1.3	6
36	Characterization and Outcomes of Disease Progression in 52 Patients Treated with BRAF-V600 + MEK Inhibitors for Advanced Melanoma. <i>Dermatology</i> , 2018, 234, 92-98.	0.9	5

#	ARTICLE	IF	CITATIONS
37	Survival estimation of melanoma patients with brain metastasis using the Melanoma-molGPA score: external validation from a French cohort. <i>Melanoma Research</i> , 2020, 30, 472-476.	0.6	5
38	Combining TNF blockade with immune checkpoint inhibitors in patients with cancer. <i>Nature Reviews Rheumatology</i> , 2021, 17, 577-577.	3.5	4
39	PD-1 inhibitors might limit the development of brain metastases in patients with advanced melanoma. <i>Melanoma Research</i> , 2020, 30, 580-589.	0.6	4
40	Aggressive locoregional behavior of cutaneous squamous cell carcinoma during ruxolitinib use. <i>Annales De Dermatologie Et De Venereologie</i> , 2021, 148, 140-141.	0.5	3
41	A case of merkel leptomenigeal evolution after complete remission upon anti-“PD-1 treatment. <i>European Journal of Cancer</i> , 2019, 113, 55-57.	1.3	2
42	Management of Autoimmune Bullous Diseases in France: A Nationwide Network of 30 Centers. <i>Dermatologic Clinics</i> , 2011, 29, 659-662.	1.0	1